HiSeq and MiSeq reads from P. knowlesi enriched, human DNA depleted, samples were deposited in the EMBL-EBI European Nucleotide Archive <http://www.ebi.ac.uk> with the archive reference for HiSeq: ERR274221; ERR274222; ERR274224; ERR274225 and MiSeq: ERR366425 and ERR366426.

Introduction {#sec001}
============

*Plasmodium knowlesi* is a malaria parasite of old world macaques that causes zoonotic malaria in humans \[[@pone.0121303.ref001]\]. *P*. *knowlesi* has been widely used as an experimental model leading to seminal discoveries in aspects of malaria biology, including antigenic variation, vaccine development and erythrocyte invasion (for example \[[@pone.0121303.ref002],[@pone.0121303.ref003],[@pone.0121303.ref004]\]). More recently, the discovery of severe cases of *P*. *knowlesi* malaria in the human population has re-kindled human-disease focussed research on this important parasite \[[@pone.0121303.ref005]\]. *P*. *knowlesi* lacks unique morphological characteristics and human infections are often mis-diagnosed as *P*. *malariae* or other *Plasmodium* species\[[@pone.0121303.ref006]\]. Novel *P*. *knowlesi*-specific PCR assays now allow accurate identification of *P*. *knowlesi* malaria and PCR-confirmed cases are continuously reported across Southeast Asia, including severe and fatal cases in Malaysia \[[@pone.0121303.ref007],[@pone.0121303.ref008],[@pone.0121303.ref009],[@pone.0121303.ref010]\].

*P*. *knowlesi* is a widespread human infectious agent in Southeast Asia, yet we currently know very little about naturally circulating parasite populations that enter the human host or the factors that are associated with severe disease. In Sarawak, Malaysian Borneo, we found that *P*. *knowlesi* parasitaemia is associated with disease severity \[[@pone.0121303.ref008],[@pone.0121303.ref009]\]. To study the relationship between parasitaemia and variation in the proteins that are involved in invasion of human erythrocytes, short regions of two *P*. *knowlesi* invasion genes, *P*. *knowlesi normocyte binding protein (Pknbp) xa* and *Pknbpxb*, were sequenced from more than 100 human infections \[[@pone.0121303.ref011]\]. Both gene fragments were polymorphic and the *Pknbpxa* fragment was dimorphic with distinct co-associating polymorphisms that segregated into two clusters. In the study cohort, patients were infected with parasites with either *Pknbpxa* dimorphic type at almost equal frequency but only alleles found in one dimorphic type associated with markers of disease severity \[[@pone.0121303.ref011]\]. While this suggests a potential link between invasion phenotypes, parasitaemia and virulence, it is critical to extend the study beyond a candidate gene level and out to the whole genome.

A reference *P*. *knowlesi* genome sequence has been generated from the macaque-adapted experimental H strain \[[@pone.0121303.ref012]\], but *P*. *knowlesi* genome sequences from clinically well-characterised isolates are not currently available. The generation of parasite genome sequences from clinical *Plasmodium* samples requires a leucocyte depletion step to minimise the amount of contaminating human DNA. However, many archived sample collections exist, including our own collection of frozen whole blood samples from patients with *P*. *knowlesi* malaria, that have not been leucocyte depleted before freezing. Adapting depletion approaches to these frozen sample sets would unlock a wealth of genomic information.

Here we report a method to deplete human DNA from frozen clinical malaria samples and render them suitable for whole genome sequencing. The method exploits two assumptions; 1) that not all leucocytes are lysed when whole blood goes through one freeze/thaw cycle and 2) the more robust parasites would survive the same treatment either in intact infected red blood cells (IRBCs) or as free parasites released from lysed erythrocytes. We developed a simple filtration method to remove leucocytes and recover parasite-rich pellets for *Plasmodium* genome sequencing. The method offers the malaria research community a means to interrogate *Plasmodium* species genome data in important archived sample collections. In this case, we use the approach to generate genome sequence data from six previously frozen *P*. *knowlesi* clinical isolates, and show that the *Pknbpxa* dimorphism may extend across the *P*. *knowlesi* genome.

Materials and Methods {#sec002}
=====================

Patient samples {#sec003}
---------------

Archived frozen whole blood samples were used from adult patients recruited into a non-interventional study with informed signed consent that included use of samples in related studies. Patient consent forms are securely stored in the University of St Andrews. Patient recruitment and consent protocols were approved by the Medical Research and Ethics Committee, Ministry of Health Malaysia and the Ethics Committee Faculty of Medicine and Health Sciences, University Malaysia Sarawak. The use of the samples in the study reported here was further approved by the University of St Andrews Teaching and Research Ethics Committee.

Human DNA depletion using Whatman filter paper {#sec004}
----------------------------------------------

EDTA blood samples from *P*. *knowlesi* patients were collected and stored at -40°C. The samples were thawed and the volume measured before gentle mixing in ice-cold PBS at a ratio of 300ul thawed blood per 5ml cold PBS. The mixture was pipetted into a 10mL syringe barrel, the base was lined with 3 layers of Whatman No 3 (6uM pore size) to remove small lymphocytes and 3 layers of Whatman No 1 (11uM pore size) on top to remove larger surviving leucocytes. The filter papers were cut to fit the internal diameter of the syringe and pre-wet with PBS before use. Not more than 10mL of diluted blood was loaded per syringe column. The filtrate was collected into sterile 50mL centrifuge tubes following centrifugation at 125g for 2 minutes at 4°C. The columns were washed through with 10mL volumes of cold PBS and each wash was collected into the filtrate tube by centrifugation as above until the filters were no longer blood-stained. The total combined filtrate, up to 40 mL, was centrifuged at 2000g for 10 minutes at 4°C to pellet any surviving IRBCs and free parasites. Pellets were re-suspended in 1ml cold PBS and transferred to 1.5ml Eppendorf tubes and recovered by centrifugation at 14,000g, for 2 minutes at 4°C. Pellets were re-suspended and washed in 1mL cold PBS and collected by centrifugation as described. This wash step was repeated two more times. The washed IRBC/parasite pellets were suspended in 20ul Proteinase K (QIAGEN) followed by 200ul cold PBS. The mixture was vortexed thoroughly before DNA extraction using QIAamp Blood Mini kit (QIAGEN) with RNase A, as per manufacturers instructions. For samples with more than 100,000 parasites /ul blood the initial blood dilution step was 150ul thawed blood into 5mL cold PBS.

TaqMan qPCR multiplexed for human and *P*. *knowlesi* DNA {#sec005}
---------------------------------------------------------

*Plasmodium* specific 18ssURNA Plasmo1: `5′ GTTAAGGGAGTGAAGACGA TCAGA` and Plasmo 2: `5′ AACCCAAAGACTTTGATTTC TCATAA` primers were used \[[@pone.0121303.ref013]\] with the published *P*. *knowlesi* TaqMan probe `5′ CTCTCCGGAGATTAGAACTCTTAGATTGCT` labelled with 5\'FAM and 3\'BHQ1 \[[@pone.0121303.ref014]\]. Human DNA primers: Plat1-A `5′ CTTACCACATCCGCTCCATC`, and Plat1-B `5′ TTCACACTCTCCGTCACATTG` with the probe `5′ HEX/CACATCCCC/ZEN/AGTGCCGAGTTAGA/3IABkFQ` were used. The qPCR master mix contained 250nM Plasmo1, 250nM Plasmo2, 250nM Plat1-A, 250nM Plat1-B, 125nM *Pk* probe, 125nM Plat1-Probe, 1 x Roche RT-PCR Master Mix and 1ul DNA template in 20ul final volume. qPCR cycling was 10 minutes at 95°C, followed by 45 cycles of 10 seconds at 95°C, 30 seconds at 57°C, and 1 second at 72°C using the Roche LightCycler 480 II.

Illumina sequencing {#sec006}
-------------------

DNA was quantified (Qubit Fluorometric Quantitation, Invitrogen, Life Technologies) and sheared into fragments of 400--600 bp. Illumina libraries were generated using a) the PCR free protocol (NoPCR) \[[@pone.0121303.ref015]\] or b) the standard library preparation using the KAPA enzyme \[[@pone.0121303.ref016]\] with eight PCR cycles. NoPCR libraries were sequenced on the Illumina HiSeq 2000 platform for 100 paired-end cycles and standard PCR libraries were sequenced on Illumina MiSeq for 150 paired ends cycles using V4 or V5 SBS sequencing kits and proprietary reagents according to manufacturer\'s recommended protocol (<https://icom.illumina.com/>). Data were analysed from the Illumina sequencing machines using RTA1.6, RTA1.8 or GA v0.3 analysis pipelines.

Reference genome {#sec007}
----------------

The *Plasmodium knowlesi* H strain reference genome version 11.1 GeneDB ([www.genedb.org/Homepage/Pknowlesi](http://www.genedb.org/Homepage/Pknowlesi)) was downloaded from PlasmoDB ([www.plasmodb.org](http://www.plasmodb.org)) \[[@pone.0121303.ref012],[@pone.0121303.ref017],[@pone.0121303.ref018]\]. The region corresponding to the *pknbpxa* gene (PKH_146970 and PKH_146980) in chromosome 14 was partially missing and fragmented in the current reference genome and we corrected for this using the published *pknbpxa* gene sequence (GenBank accession number EU867791.1) \[[@pone.0121303.ref002]\]. Common non-coding DNA regions upstream and downstream of the *pknbpxa* gene were located in both the *Plasmodium knowlesi* strain H reference genome and the published *pknbpxa* gene. With this information it was possible to replace the *pknbpxa* gene (PKH_146970) in the reference genome sequence with the published EU867791.1 gene sequence without disrupting subsequent mapping. The *pknbpxb* gene, which was not annotated correctly, was rectified using the EU867792.1 published gene sequence \[[@pone.0121303.ref002]\].

Genome sequence mapping {#sec008}
-----------------------

HiSeq and MiSeq reads from *P*. *knowlesi* enriched, human DNA depleted, samples are deposited in the EMBL-EBI European Nucleotide Archive (<http://www.ebi.ac.uk>)\[[@pone.0121303.ref019]\]. The archive references are for HiSeq: ERR274221; ERR274222; ERR274224; ERR274225 and MiSeq: ERR366425 and ERR366426. Sequences mapping to the human genome, representing patient DNA, were removed from this data in the sequencing pipeline. The reads were mapped to the corrected *P*. *knowlesi H* strain reference genome sequence (PlasmoDB-11.1_PknowlesiH_Genome.fasta) using Bowtie-2 \[[@pone.0121303.ref020]\] followed by Bedtools to summarise the coverage of each genome \[[@pone.0121303.ref021]\].

Single Nucleotide Polymorphism (SNP) calling {#sec009}
--------------------------------------------

Samtools mpileup with threshold base quality set to 13 was used with BCFtools to generate Variant Call SNP Format (VCF) files for each *P*. *knowlesi* genome sequence \[[@pone.0121303.ref022]\]. A varFilter (BCFtools) was applied and all SNP sites with allele frequency less than 0.9 were removed. Insertions and deletions were not included in any of the analyses or scripts. Only SNP sites with a minimum coverage of 13 were taken into consideration.

Linkage Disequilibrium analysis of full-length *pknbpxa* sequences extracted from *P*. *knowlesi* genome sequence data {#sec010}
----------------------------------------------------------------------------------------------------------------------

We used Artemis \[[@pone.0121303.ref012],[@pone.0121303.ref017],[@pone.0121303.ref023],[@pone.0121303.ref024]\] and the VCF files to generate full-length *pknbpxa* gene sequences as fasta files from each of the genome sequences (n = 6). The fasta files were converted to the Haploview compatible PLINK format \[[@pone.0121303.ref025]\]. Linkage disequilibrium was performed on the full-length coding region of *Pknbpxa* sequences using Haploview and analysed using default parameters \[[@pone.0121303.ref026],[@pone.0121303.ref027]\]. Nucleotide diversity (π) was calculated using a 400bp window length with a step size of 25bp, DnaSP \[[@pone.0121303.ref028]\].

Identification of polymorphisms genome-wide co-associating with the *Pknbpxa* fragment dimorphism {#sec011}
-------------------------------------------------------------------------------------------------

An algorithm was developed to identify SNP sites in each genome sequence (n = 6), co-associating with the *P*. *knowlesi Pknbpxa* dimorphic pattern already identified in a small fragment of this gene \[[@pone.0121303.ref011]\] and also visible in Artemis on chromosome 14 at the *Pknbpxa* locus ([Fig. 1](#pone.0121303.g001){ref-type="fig"}). Briefly the script was designed to screen VCF files to identify each SNP and test if the SNP co-associated with SNPs defining the *Pknbpxa* dimorphism. Co-associating patterns were predefined in the algorithm to describe which kind of symbols (SNP pattern) each genome required to fit within either of the *P*. *knowlesi Pknbpxa* dimorphic forms. Every time a SNP fit the pattern the event was signalled (recorded). Finally, an image was created to show the density of all SNP sites and then the co-associating SNPs for each chromosome ([S1 Fig](#pone.0121303.s001){ref-type="supplementary-material"}.).

![A screen shot of Artemis DNA view comparing six *Plasmodium knowlesi* genome sequences from patient isolates to the *Plasmodium knowlesi* H strain reference genome sequence.\
The *P*. *knowlesi normocyte binding protein xa* locus on chromosome 14 is shown. The screen shot shows segregation of the sequences from patient isolates into two groups, (n = 3 in each group) and the dimorphism is clearly visible.](pone.0121303.g001){#pone.0121303.g001}

Testing the distribution of co-associated SNPs defined in the *Pknbpxa* dimorphism {#sec012}
----------------------------------------------------------------------------------

To identify positions on each *P*. *knowlesi* chromosome where the density of co-associating sites was more evident a Chi square test of independence was applied followed by a calculation of adjusted residuals. For this, each chromosome was divided into 30 equal parts and a contingency table was created to reflect the number of SNPs co-associating with the *Pknbpxa* dimorphism per part per chromosome. Adjusted residuals were calculated in a contingency table and a threshold of \> 3.00 for more co-associating SNPs than expected and \< -3.00 for less co-associating dimorphic SNPs than expected was applied to the resulting values. By applying these thresholds it was possible to identify, within 99.7% limits of confidence, co-associating SNP sites for each chromosome with higher or lower than expected co-associating SNP density.

Gene Ontology (GO) {#sec013}
------------------

*P*. *knowlesi* genes were analysed using Blast2GO <http://www.blast2go.com> version 2.7.2 \[[@pone.0121303.ref029]\]. All genes with complete coverage (4623) were blasted against nr\@ncbi database and an InterProScan 5 analysis was performed \[[@pone.0121303.ref030]\]. The Gene Ontology classification was done with default parameters \[[@pone.0121303.ref031]\]. Genes with no (0) co-associating SNP sites, with \>0--\<10 (1--9) and \>9 (≥ 10) SNPs that co-associated with the *P*. *knowlesi* genome-wide dimorphism were identified within each resulting GO group.

Testing for enrichment of dimorphic genes in particular GO subgroups {#sec014}
--------------------------------------------------------------------

Genes with dimorphic SNP sites were tested for statistically significant enrichment of dimorphic genes in GO subgroups using *topGO* Enrichment analysis for Gene Ontology. R package version 2.14.0. Adrian Alexa and Jorg Rahnenfuhrer (2010). (<http://www.bioconductor.org/packages/release/bioc/html/topGO.html>). For this we selected two groups of genes those with one or more dimorphic SNP sites (≥1) and a separate group with ten or more dimorphic SNP sites (≥10) and analysed for enrichment against all genes with at least one SNP whether or not dimorphic.

Results {#sec015}
=======

Human DNA depletion from frozen whole blood samples {#sec016}
---------------------------------------------------

Frozen whole blood samples from fifteen *P*. *knowlesi* patients, with parasite counts ranging from 10,000--400,000 parasite/ul, were thawed and human DNA depleted using an in-house method. Briefly white blood cells were removed by filtration through Whatman filter paper followed by parasite recovery as described in detail (see [Methods](#sec002){ref-type="sec"} section). Total human and parasite DNA was quantified using qPCR ([Table 1](#pone.0121303.t001){ref-type="table"}). Nine of fifteen isolates had the required \>100ng of *P*. *knowlesi* DNA, and seven of the nine had \<80% human DNA contamination, the cut-off for *Plasmodium* genome sequencing, and were suitable for sequencing ([Table 1](#pone.0121303.t001){ref-type="table"}). Five and two DNA samples were used to generate NoPCR and PCR sequencing libraries and multiplexed in a single lane on Illumina HiSeq and MiSeq platforms respectively ([Table 1](#pone.0121303.t001){ref-type="table"}). The remaining six samples had insufficient *P*. *knowlesi* DNA and/or \>80% human DNA (hDNA) contamination ([Table 1](#pone.0121303.t001){ref-type="table"}).

10.1371/journal.pone.0121303.t001

###### Clinical samples human DNA depleted using the Whatman filtration method.

![](pone.0121303.t001){#pone.0121303.t001g}

  Sample ID   Parasites/ul   Accession ID[^§^](#t001fn006){ref-type="table-fn"}   Total hDNA (ng) qPCR   Total Pk DNA (ng) qPCR   \% Pk DNA
  ----------- -------------- ---------------------------------------------------- ---------------------- ------------------------ -----------
  47          128,500        ND                                                   302                    294                      49.3
  Duplicate                  ERR366425[\*](#t001fn002){ref-type="table-fn"}       131                    238                      64.5
  87          47,000         NS                                                   225                    51                       18.7
  Duplicate                  NS                                                   6                      8                        56
  73          40,000         ERR366426[\*](#t001fn002){ref-type="table-fn"}       33                     233                      87.6
  Duplicate                  ND                                                   106                    162                      60.4
  91          29,000         NS                                                   269                    37                       12
  220         10,000         NS                                                   735                    24                       3.1
  48          86,000         ND                                                   1402                   1167                     45.4
  Duplicate                  ERR274221[\*\*](#t001fn003){ref-type="table-fn"}     421                    824                      65.7
  50A         139,000        ERR274222[\*\*](#t001fn003){ref-type="table-fn"}     317                    2775                     89.8
  Duplicate                  ND                                                   415                    3280                     88.8
  50B         390,000        ERR274223                                            597                    1239                     67.5
  55          186,500        NS                                                   1235                   428                      25.7
  Duplicate                  NS                                                   3418                   433                      11.2
  58          149,000        ERR274224[\*\*](#t001fn003){ref-type="table-fn"}     336                    506                      60
  62          139,000        NS                                                   988                    71                       6.7
  178         104,000        NS                                                   103                    11                       9.4
  233         326,000        NS                                                   1015                   313                      23.5
  258         58,000         NS                                                   560                    94                       14.3
  Duplicate                  NS                                                   245                    59                       19.4
  299         66,000         ERR274225[\*\*](#t001fn003){ref-type="table-fn"}     626                    984                      61.1

Samples sequenced using Illumina HiSeq or MiSeq sequencing platforms are labelled. The amount of Parasite DNA recovered and per cent human DNA contamination are given.

\*MiSeq.

\*\*HiSeq.

NS = Not suitable.

ND = Duplicate sample suitable but not sequenced.

^§^ Accession number EMBL-EBI European Nucleotide Archive (<http://www.ebi.ac.uk>).

DNA obtained from frozen *P*. *knowlesi* clinical isolates generated high coverage genome sequence {#sec017}
--------------------------------------------------------------------------------------------------

*P*. *knowlesi* sequence data was generated from seven patient isolates, five from HiSeq runs and two from MiSeq runs. The HiSeq runs generated \>36 million reads and MiSeq \>5 million reads. An average mapping of \>90% was obtained for both HiSeq and MiSeq data producing an average coverage of \>140x for HiSeq and \>30x for MiSeq. The total number of reads mapped and not mapped, percent human DNA contamination and coverage per genome sequence are summarized in [Table 2](#pone.0121303.t002){ref-type="table"}.

10.1371/journal.pone.0121303.t002

###### *P*. *knowlesi* clinical isolate genome sequence summary report.

![](pone.0121303.t002){#pone.0121303.t002g}

  Sequence ID              ERR366426   ERR366425   ERR274221   ERR274223   ERR274222   ERR274225   ERR274224
  ------------------------ ----------- ----------- ----------- ----------- ----------- ----------- -----------
  Technology               MiSeq       MiSeq       HiSeq       HiSeq       HiSeq       HiSeq       HiSeq
  Sample Ref.              SKS-047     SKS-073     SKS-048     SKS-050B    SKS-050A    SKS-299     SKS-058
  Total Reads              6003990     6130562     45217760    47211338    58756176    51769792    41469862
  Total Reads Mapped       4731148     5049125     37095534    38967367    48466910    43203711    34547072
  Total Reads Not Mapped   1272842     1081437     8122226     8243971     10289266    8566081     6922790
  \% Reads Not Mapped      21          17          17          17          17          16          16
  \% Human DNA             1.58        1.59        0.75        0.48        0.14        0.71        0.73
  Coverage                 32          34          166         175         218         195         156
  Number of SNPs           267055      260888      318427      317051      317072      304641      304147
  Number Dimorphic SNPs    42771       42771       42771       42771       42771       42771       42771
  \% Zero Coverage (%)     7.8         7.9         5.5         5.8         5.8         5.9         6
  Coverage \>1 (%)         91.6        91.4        94.1        93.9        93.9        93.7        93.6
  Coverage \>5 (%)         90.1        89.9        93.5        93.3        93.4        93.1        92.9
  Coverage \>10 (%)        88.4        88.4        92.9        92.8        93          92.6        92.4

Genome Size 23487363

*P*. *knowlesi* genome analysis {#sec018}
-------------------------------

The reads were mapped to the *P*. *knowlesi* H strain reference genome following correction of the *Pknbpxa* locus (see [materials and methods](#sec002){ref-type="sec"} section). Two genome sequences (ERR274222 and ERR274223) were generated from a single patient representing pre- and post-treatment samples. Only the pre-treatment sample sequence, ERR274222, was included in subsequent analyses along with sequences from five other patients all collected pre-treatment.

The sequences covered 5228 genes, including genes and gene fragments annotated as genes of un-known function. Data from 605 genes were excluded because coverage was zero at one or more base position leaving 4623 genes in subsequent analyses. This filter excluded all but five of the 195 SICAVar genes and gene fragments and all but three of the 67 KIR genes and gene fragments. Both of these gene families are highly polymorphic, and the gene sequences in these contemporary clinical isolates are likely to be very different to those in the historical monkey-adapted reference genome, so mapping issues and low coverage in these gene sets is to be expected. Of the remaining genes 2180 (47.2%) were annotated as genes with unknown function. The SNP distribution across the genome is shown in [S1 Fig](#pone.0121303.s001){ref-type="supplementary-material"}.

Dimorphism extends across and beyond *Pknbpxa* {#sec019}
----------------------------------------------

In a previous study we identified a DNA sequence dimorphism in a fragment (885bp) representing 10% of the *P*. *knowlesi* normocyte binding protein (*Pknbp)xa* gene that codes for a protein involved in red blood cell invasion. To determine the extent of the dimorphism across the gene, full-length *Pknbpxa*, (PKH_146970) coding sequences were assembled from the six genome sequences obtained from the same patient cohort. Ninety-one (91) *Pknbpxa* SNPs co-associated with the dimorphic pattern (r^2^ = 1). This dimorphism effectively divides the *Pknbpxa* gene sequences into two clusters of sequence types, with *Pknbpxa* sequences from three genomes falling into cluster 1 and three into cluster 2. Nucleotide diversity (π) was higher across the clusters (π = 0.01441), than it was within each cluster, (π = 0.00518 for cluster 1 (n = 3) and π = 0.00868 for cluster 2; n = 3 each). Cluster 1 was less diverse than cluster 2, consistent with *Pknbpxa* nucleotide diversity found in the previous study, but the significance of this difference cannot be estimated based on six sequences.

The *P*. *knowlesi* genome sequences from clinical isolates were viewed in Artemis, a genome browser and annotation tool and referenced to the *P*. *knowesi* H strain genome sequence. Two SNP patterns emerged and the *Pknbpxa* dimorphism was clearly visible with sequences from three patient isolates clustering into each pattern ([Fig. 1](#pone.0121303.g001){ref-type="fig"}). To test whether the dimporphism extended beyond the boundaries of the *Pknbpxa* gene, SNP association with the *Pknbpxa* dimorphism was examined first along chromosome 14 and then genome-wide using an in-house script (see [Materials and Methods](#sec002){ref-type="sec"} section). The dimorphic SNP pattern was evident at multiple genetic loci on all chromosomes ([S1 Fig](#pone.0121303.s001){ref-type="supplementary-material"}.). The relative distribution of co-associated SNPs on each chromosome was determined by dividing each chromosome into 30 equal parts and using the Chi squared test of independence to test expected and observed events ([S1 Table](#pone.0121303.s002){ref-type="supplementary-material"}). Although the dimorphism extends across the full genome, the intensity and distribution is not uniform or clustered in any particular chromosomal region. The position and number of non-synonymous and synonymous SNPs co-associating with the dimorphism per gene per chromosome are represented in [Fig. 2](#pone.0121303.g002){ref-type="fig"}.

![The number and position of SNP sites per gene co-associating with the *P*. *knowelsi* genome-wide dimorphism.\
Non-synonymous polymorphisms (red) are shown above the line and synonymous polymorphisms (blue) are shown below the line. The line is drawn at zero. The chromosomes are drawn to scale and the height of the bars represents the number of SNP sites per gene per region of each chromosome. The scale is given in the boxed area and is the number of SNP sites per gene.](pone.0121303.g002){#pone.0121303.g002}

More than half of the *P*. *knowlesi* genes in the genome, 2801 of 4623 genes (60.8%), appear to be dimorphic. Within the dimorphic group the number of dimorphic SNP sites per gene varied widely. For example, while *Pknbpxa* had a total of 326 SNPs, of which 91 (27.9%) co-associated with the dimorphism, a related gene of similar size, *Pknbpxb*, had a total of 197 SNPs of which only 5 (2.2%) co-associated with the dimorphism ([S2 Table](#pone.0121303.s003){ref-type="supplementary-material"}). Applying a more conservative cut-off identified 507 genes with ≥10 co-associating SNPs, representing 11% of genes in the genome with adequate coverage. Of these 301 (59.5%) were annotated as genes of unknown function. The chromosome location and annotated function of the remaining 206 genes is listed in [S2 Table](#pone.0121303.s003){ref-type="supplementary-material"}. Notable genes within this high stringency dimorphic group included 12 of 27 (44%) of genes annotated as transcription factors with AP2 domains in the *P*. *knowlesi* genome. Several genes associated with drug resistance in other *Plasmodium* species, such as putative multi drug resistance-associated protein PkMRP1(PKH_144590) and putative multidrug resistance protein, PkMDR 2 (PKH_125840) [S2 Table](#pone.0121303.s003){ref-type="supplementary-material"}, were also dimorphic, while the putative chloroquine resistance transporter (CRT) gene (PKH_010710) had 23 SNPs, none were dimorphic and only one SNP conferred an amino acid change.

The enrichment of dimorphic genes among genes encoding transcription factors with AP2 domains was obvious and identified manually. We then used Gene Ontology (GO), (Blast2GO) tools to examine whether other *P*. *knowlesi* dimorphic genes were enriched in GO groups that served particular biological functions. Genes were sorted into GO term groups and sub-groups with putative or known molecular function, cellular process activity and biological process activity ([Table 3](#pone.0121303.t003){ref-type="table"}). We then calculated the proportion genes with ≥1 dimorphic SNP in each GO group ([Table 3](#pone.0121303.t003){ref-type="table"}). Most of the GO term groups had, as expected, approximately 60% dimorphic genes but there was variation ([Table 3](#pone.0121303.t003){ref-type="table"}). If dimorphic genes have evolved randomly over time then the proportion of genes with dimorphic SNP sites in the GO groups would not be expected to be different from the distribution of genes with dimorphic SNP sites in the whole genome that is: 39% of genes with no dimorphic SNPs; 50% of genes with 1--9 dimorphic SNPs and 11% of gene with ten or more dimorphic SNPs. Several GO sub-groups had more genes than expected with 1--9 dimorphic SNP sites and ≥10 dimorphic SNP sites for example genes with molecular transducer activity, nucleic acid binding transcription factor activity and membrane association ([Fig. 3a, 3b and 3c](#pone.0121303.g003){ref-type="fig"}). There were also sub-groups of genes where dimorphic SNP sites were under-represented, including structural and molecular activity, developmental process and immune system process ([Table 3](#pone.0121303.t003){ref-type="table"} and [Fig. 3](#pone.0121303.g003){ref-type="fig"}). We used *topGO* to test for statistically significant enrichment of dimorphic genes in GO term groups ([Table 4](#pone.0121303.t004){ref-type="table"}). In the first instance all genes with at least one dimorphic SNP were analysed and there was significant enrichment, particularly in the ion binding function, helicase activity and tRNA metabolic process function GO term groups ([Table 4](#pone.0121303.t004){ref-type="table"}). Genes with ≥10 dimorphic SNPs were significantly enriched in the nucleic acid binding transcription factor activity and kinase activity GO term groups ([Table 4](#pone.0121303.t004){ref-type="table"}).

10.1371/journal.pone.0121303.t003

###### Summary of *P*. *knowlesi* gene ontology (GO) analysis and the proportion of genes in each group with dimorphic SNP\'s.

![](pone.0121303.t003){#pone.0121303.t003g}

  Gene ontology (GO) group   GO-ID                                                GO- subgroup                    Total number of genes   Total genes in dimorphism   Proportion in dimorphism
  -------------------------- ---------------------------------------------------- ------------------------------- ----------------------- --------------------------- --------------------------
  **Molecular function**     GO:0060089                                           Molecular transducer activity   5                       3                           0.60
  GO:0000988                 Protein binding transcription factor activity        8                               4                       0.50                        
  GO:0001071                 Nucleic acid binding transcription factor activity   31                              23                      0.74                        
  GO:0030234                 Enzyme regulator activity                            41                              24                      0.59                        
  GO:0005215                 Transporter activity                                 101                             63                      0.62                        
  GO:0005198                 Structural molecule activity                         151                             67                      0.44                        
  GO:0003824                 Catalytic activity                                   999                             653                     0.65                        
  GO:0005488                 Binding                                              1031                            664                     0.64                        
  **Cellular Processes**     GO:0031012                                           Extracellular matrix            1                       0                           0.00
  GO:0005576                 Extracellular region                                 6                               3                       0.50                        
  GO:0031974                 Membrane-enclosed lumen                              55                              34                      0.62                        
  GO:0016020                 Membrane                                             15                              12                      0.80                        
  GO:0005623                 Cell                                                 1054                            573                     0.54                        
  GO:0043226                 Organelle                                            813                             423                     0.52                        
  GO:0032991                 Macromolecular complex                               447                             229                     0.51                        
  **Biological processes**   GO:0051704                                           Multi-organism process          5                       4                           0.80
  GO:0002376                 Immune system process                                3                               1                       0.33                        
  GO:0022610                 Biological adhesion                                  4                               4                       1.00                        
  GO:0032502                 Developmental process                                8                               2                       0.25                        
  GO:0040011                 Locomotion                                           10                              5                       0.50                        
  GO:0000003                 Reproduction                                         7                               3                       0.43                        
  GO:0023052                 Signaling                                            72                              40                      0.56                        
  GO:0065007                 Biological regulation                                109                             59                      0.54                        
  GO:0071840                 Cellular component organization or biogenesis        184                             99                      0.54                        
  GO:0050896                 Response to stimulus                                 157                             93                      0.59                        
  GO:0051179                 Localization                                         255                             155                     0.61                        
  GO:0044699                 Single-organism process                              264                             149                     0.56                        
  GO:0009987                 Cellular process                                     1215                            721                     0.59                        
  GO:0008152                 Metabolic process                                    1211                            716                     0.59                        

Gene Ontology assigned using Blast2GO---Software for Biologists, <http://www.blast2go.com>.

![*P*. *knowlesi* genes are grouped by gene ontology (GO) terms.\
The percent of genes in each GO sub-group of a) molecular function, b) cellular processes and c) biological processes are shown, n = the total number of mapped annotated genes in each GO sub-group. Percent of genes in GO subgroups with: no dimorphic SNP sites shown in brown, genes with 1--9 dimorphic SNP sites turquoise and genes with ≥10 dimorphic SNP sites purple. The expected percent of genes with 1--9 dimorphic SNPs (50%) is marked with a turquoise hatched line and the expected percent of genes with ≥10 dimorphic SNPs (11%) is marked with a purple hatched line. Gene ontology was assigned using Blast2GO---Software for Biologists, <http://www.blast2go.com>.](pone.0121303.g003){#pone.0121303.g003}
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###### *topGO* gene enrichment analysis.

![](pone.0121303.t004){#pone.0121303.t004g}

  Gene Ontology (Blast\@GO)                                      *topGO* term functional description                  *topGO* ID   ≥1 dimorphic SNPs   ≥10 dimorphic SNPs
  -------------------------------------------------------------- ---------------------------------------------------- ------------ ------------------- --------------------
  **Molecular Function**                                                                                                           *p* =               *p* =
  Binding                                                        Ion binding                                          GO:0043167   0.000077            0.01011
  Catalytic activity                                             Helicase activity                                    GO:0004386   0.000095            
  Catalytic activity                                             ATPase activity                                      GO:0016887   0.0014              0.02964
  Catalytic activity                                             Hydrolase activity, acting on glycosyl bonds         GO:0016798   0.0328              
  Catalytic activity                                             DNA binding                                          GO:0003677   0.0121              
  Catalytic activity                                             GTPase activity                                      GO:0003924   0.0421              
  Nucleic acid binding transcription factor activity             Nucleic acid binding transcription factor activity   GO:0001071                       0.000037
  Catalytic activity                                             Kinase activity                                      GO:0016301                       0.00067
  **Cellular Component**                                                                                                                               
  Cell; Organelle                                                Microtubule organizing center                        GO:0005815   0.021               
  Cell                                                           Plasma membrane                                      GO:0005886   0.037               
  Cell; Organelle                                                Nucleus                                              GO:0005634                       0.0029
  Cell; Organelle                                                Cytoskeleton                                         GO:0005856                       0.0402
  **Biological Process**                                                                                                                               
  Metaboloc process; Cellular process                            tRNA metabolic process                               GO:0006399   0.00033             
  Metaboloc process; Cellular process                            Cellular amino acid metabolic process                GO:0006520   0.00357             
  Single-organism process; Metaboloc process; Cellular process   Mitosis                                              GO:0007067   0.00849             
  Metaboloc process; cellular process                            Nucleobase-containing compound catabolic process     GO:0034655   0.01453             
  Multi-organism process                                         Transport                                            GO:0006810   0.03512             
  Metaboloc process; cellular process                            Cellular protein modification process                GO:0006464   0.03678             
  Metaboloc process; cellular process                            Cellular nitrogen compound metabolic process         GO:0034641                       0.028

Discussion {#sec020}
==========

Here we describe a method for enriching *Plasmodium* DNA from frozen whole blood samples collected from patients with malaria. The method required at least 200ul of whole blood at \>40,000 parasites/ul to obtain sufficient parasite DNA for genome sequencing platforms. Parasite DNA recovery was inconsistent and human DNA contamination was the main problem. Nonetheless, seven of fifteen patient samples had sufficiently enriched *P*. *knowlesi* DNA to produce high quality genome sequences using Illumina sequencing platforms. The success may in part be because *P*. *knowlesi* is less AT rich (62%) than other *Plasmodium* genomes \[[@pone.0121303.ref012]\] perhaps reducing amplification bias. Combining the frozen sample filtration method described here with methylated DNA digestion and target enriched sequencing approaches described by others \[[@pone.0121303.ref016],[@pone.0121303.ref032]\], may yield valuable *Plasmodium* genome data from many precious pre-existing frozen clinical sample collections.

In a previous study we identified a sequence dimorphism in a fragment (885bp) of the *P*. *knowlesi* normocyte binding protein (*Pknbp)xa* that codes for a protein involved in red blood cell invasion \[[@pone.0121303.ref011]\]. *Pknbpxa* dimorphic cluster 2 contained alleles associated with markers of disease severity implying that dimorphic cluster 2 may contain more virulent parasites than cluster 1. Our genome data revealed that the dimorphism extended along the full-length (\>8000bp) *Pknbpxa* coding region, along chromosome 14 and beyond. SNPs co-associating with the *Pknbpxa* dimorphism were distributed genome-wide across all chromosomes.

Interestingly, even within the limitation that only six samples were sequenced, the dimorphism comprised numerous non-synonymous substitutions, suggesting, for the first time, that there may be at least two distinct types of *P*. *knowlesi* circulating in Sarawak, Malaysian Borneo, and that some may be more virulent that others. Dimorphic loci have been described in many *Plasmodium* species, particularly in merozoite surface antigens and invasion ligands of *P*. *falciparum* and *P*. *vivax* \[[@pone.0121303.ref033],[@pone.0121303.ref034],[@pone.0121303.ref035]\]. In *P*. *ovale* dimorphic characteristics at selected loci prompted the division of *P*. *ovale* into two sub-species \[[@pone.0121303.ref035]\]. Even so the evolution and maintenance of allelic dimorphisms in *Plasmodium* species is difficult to explain \[[@pone.0121303.ref034]\]. Here we demonstrate a genome-wide dimorphism, involving more than half of the genes in the *P*. *knowlesi* genome, including genes coding for functions that transcend from exposed parasite surfaces to protected internal sites. The sub-division of *P*. *knowlesi* into distinct types will require further sequence confirmation, yet the genome-wide nature of the dimorphism is striking.

Although there was significant enrichment of dimorphic genes in several GO functional groups it is not clear what is driving a genome-wide dimorphism in *P*. *knowlesi*. Interestingly twelve genes implicated in parasite lifecycle stage-specific transcription, the putative transcription factors with Apicomplexan Apetala2 (AP2) domains \[[@pone.0121303.ref036],[@pone.0121303.ref037],[@pone.0121303.ref038],[@pone.0121303.ref039]\] were dimorphic. Variation at these loci may mark genetically distinct lifecycle characteristics isolating *P*. *knowlesi* into strains or subspecies. In addition, all nine members of the ABC, ABC C transporter protein family of genes, annotated in the *P*. *knowlesi* genome, were dimorphic \[[@pone.0121303.ref012],[@pone.0121303.ref040]\]. These genes are found in all phyla and represent an ancient gene family that, in eukaryotes, expel a wide range of unwanted substrates \[[@pone.0121303.ref041]\]. This family of genes include *P*. *knowlesi PkMDR2* and *PkMRP1* that were both polymorphic and dimorphic implying selection pressure at these loci. *PkMDR2* and *PkMRP1* are orthologues of *P*. *falciparum PfMDR 2* and *PfMRP1*, genes that carry genetic markers of drug resistance, including resistance to mefloquine \[[@pone.0121303.ref040],[@pone.0121303.ref042]\]. Tantalizingly, experimental lines of *P*. *knowlesi* were found innately resistant to mefloquine in Rhesus monkeys and clinical isolates did not respond well to mefloquine *ex vivo* \[[@pone.0121303.ref043],[@pone.0121303.ref044]\]. Patients with uncomplicated *P*. *knowlesi* infections responded to mefloquine but one patient with severe disease exhibited RIII type resistance \[[@pone.0121303.ref045],[@pone.0121303.ref046],[@pone.0121303.ref047]\].

Selection at these promiscuous transporter loci in zoonotic parasites that, unlike *P*. *falciparum*, are not under conventional drug selection pressure may at first seem surprising. However, domestic and wild animals eat plants with bio-active properties---they self-medicate \[[@pone.0121303.ref048]\]. The jungles of Sarawak are considered un-mined treasure-troves of plant species with medicinal properties that are freely available to the animal species living there, including the macaque reservoir of *P*. *knowlesi* \[[@pone.0121303.ref049]\]. Selection at *Plasmodium* loci, that have evolved to eliminate natural toxins, then assumes biological relevance. Unfortunately these loci also evolve to eliminate antimalarial compounds when used to treat patients with malaria.

*P*. *knowlesi* is a relatively \'un-tamed\' *Plasmodium* species, therefore *P*. *knowlesi* genomes may retain ancient and diverse genetic signatures, that are presently invisible in heavily drug selected human-host restricted parasite populations such as *P*. *falciparum* and *P*. *vivax*. High throughput pathogen genome sequencing is a powerful new tool for infectious disease research. Here we use Illumina HiSeq and MiSeq platforms to produce high quality *P*. *knowlesi* genome sequences from difficult archived frozen samples. Analysis of the sequences uncovered a *P*. *knowlesi* genome-wide dimorphism that suggests there are least two types of *P*. *knowlesi* parasites in our patient cohort. We further discovered dimorphic genes among transporter genes that are important in antimalarial drug resistance. Genome-wide pathogen analyses, of even a small number of clinical malaria isolates, instantly added context to our understanding of *Plasmodium* pathobiology, particularly through between-species comparison.

Supporting Information {#sec021}
======================

###### *P*. *knowlesi* genome SNP density map.

Six *P*. *knowlesi* genome sequences from patient isolates were mapped to the *P*.*knowlesi* reference genome. Sites that differ from the reference are shown as blue bars (all SNP sites) or grey bars (SNP sites co-associating with the *P*. *knowlesi* genome-wide dimorphism). Each bar is 1 pixel wide and represents DNA fragments 809 bases long. The height of the bars represents the number of SNP sites per 809 base fragment. Gaps correspond to regions with low coverage (see [results](#sec015){ref-type="sec"} section) or where the reference genome is incomplete (runs of \'N\').

(PNG)

###### 

Click here for additional data file.

###### Distribution of co-associating SNPs by chromosome in six *P*. *knowlesi* genome sequences from human isolates.

Each chromosome was divided into 30 equal parts.

(PDF)

###### 

Click here for additional data file.

###### List of annotated genes from six clinical isolates with \>9 SNPs that co---associate with the *Plasmodium knowlesi* genome-wide dimorphism.

(PDF)

###### 

Click here for additional data file.
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